Update shared on07 Aug 2025
Fair value Increased 7.41%Smith & Nephew's consensus analyst price target has risen to £13.30, reflecting a lower expected future P/E and slightly stronger revenue growth forecasts.
What's in the News
- Smith+Nephew launched the Q-FIX KNOTLESS All-Suture Anchor, featuring market-leading fixation strength, proprietary suture lock mechanism, and streamlined suture shuttling for various joint repairs.
- The company introduced the TRIGEN MAX Tibia Nailing System, the only side-specific tibial nail system in the US, designed to improve fixation, minimize soft tissue irritation, and enhance surgical efficiency.
- Smith+Nephew entered a strategic partnership with Standard Health to develop the UK’s first Orthopaedic Ambulatory Surgery Centre, supplying medical technologies to address growing NHS waiting lists and replicating successful US ASC models.
- A new medial stabilized insert for the LEGION Total Knee System was announced, aligning with rising market trends in knee arthroplasty and offering improved stability and OR efficiency, initially available in the US and Canada.
- Smith+Nephew secured a 10-year, $75 million contract to supply RENASYS TOUCH NPWT systems to the US Department of Defense, supporting military wound care; and published favorable clinical data showing its PICO sNPWT reduces C-section complications and associated patient burdens.
Valuation Changes
Summary of Valuation Changes for Smith & Nephew
- The Consensus Analyst Price Target has risen from £12.62 to £13.30.
- The Future P/E for Smith & Nephew has significantly fallen from 21.31x to 16.12x.
- The Consensus Revenue Growth forecasts for Smith & Nephew has risen slightly from 5.2% per annum to 5.4% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.